Trial Profile
Efficacy and Safety of Anlotinib Combined With Platinum Plus Pemetrexed in T790M Mutation Negative Metastastic Non-squamous Non-small-cell Lung Cancer After Progression on First-line EGFR TKI: a Phase II, Muti-center, Single Arm Study
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Jan 2021 Results (n=15) presented at the 2020 World Conference on Lung Cancer
- 02 Apr 2020 Status changed from not yet recruiting to recruiting.
- 22 Oct 2018 New trial record